ABSTRACT
Objective Each nation develops a guideline for managing and preventing cardiovascular disease (CVD) based on the available literature and the evidence-based consensus in their guideline’s recommendations. The goal of this review is to appraise the quality of many guidelines recommended by several international organizations for the early detection and prevention of CVD.
Methods We conducted a scoping review using a few guideline-specific databases using Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) as the reporting guideline for this review. We used the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument to rate the methodological quality and rigorousness of the included guidelines for CVD prevention and early detection.
Results Out of the 2,466 guidelines identified by our search, based on our eligibility criteria, we included a total of 20 distinct guidelines globally focused on screening for CVD prevention and early detection. (70%) of these guidelines were classified as "strongly recommended" while only (90%) were classified as just "recommended". The AGREE II appraisal domains with the highest median scores (percentile 25th, 75th) were “Clarity of Presentation” 92% (81, 95.5), followed by Applicability 88% (73, 93). The Rigour of Development and Editorial Independence were the lowest scores with a median of 78% (66.5, 84) and 75% (60.5, 92).
Conclusions Using AGREE II quality appraisal tool, we provided a critical quality appraisal of several international CVD prevention guidelines and reveal opportunities to improve the CVD prevention guidelines’ quality.
What is already known in this review?
Each community develops a guideline for screening and managing CVD prevention based on the current evidence and evidence-based consensus.
AGREE II tool is an internationally standardized instrument to report the rigorousness of development, transparency, and methodological quality of the clinical practice guidelines.
What this review adds
This review provided a critical quality appraisal of several international CVD prevention guidelines.
The highest AGREE II domain median score was “Clarity of Presentation” while the least domains were “Editorial Independence” and “Rigour of Development”.
70% of these guidelines were classified as "strongly recommended".
How this review might affect research, practice, or policy
This review provided a critical quality appraisal of many CVD prevention guidelines and revealed opportunities to improve CVD prevention guidelines’ quality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Universiti Brunei Darussalam, Brunei Darussalam.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
ABBREVIATIONS
- ACCF/AHA
- The American College of Cardiology Foundation and the American Heart Association
- ADA
- American Diabetes Association
- AGREE II
- Appraisal of Guidelines for Research and Evaluation II
- AHA/ACC
- The American Heart Association and The American College of Cardiology
- ASSIGN
- ASsessing cardiovascular risk using SIGN guidelines to ASSIGN preventive treatment
- CAD
- coronary artery disease
- C-CHANGE
- Canadian Cardiovascular Harmonized National Guidelines Endeavour
- CHD
- Coronary heart disease.
- CPG
- Clinical practice guideline
- CVD
- Cardiovascular disease
- CVDRA
- CVD risk assessment
- EAPC
- European Association of Preventive Cardiology
- ESC
- European Society of Cardiology
- GRADE
- The Grading of Recommendations Assessment, Development and Evaluation
- ISH
- International Society of Hypertension
- JBS
- Joint British Societies’ Guidelines
- Max.
- Maximum
- Min.
- Minimum
- MOH
- Ministry of Health
- NCDs
- Noncommunicable Diseases
- NCEP ATP
- National Cholesterol Education Program’s Adult Treatment Panel
- NHMRC
- National Health and Medical Research Council
- NHS
- National Health Services
- NICE
- National Institute for Health and Care Excellence
- NVDPA
- The National Vascular Disease Prevention Alliance
- PRISMA-ScR
- Systematic reviews and Meta-Analyses extension for Scoping Reviews
- SCORE
- Systematic Coronary Risk Estimation
- SCORE2-OP
- Updated SCORE for old people
- SHAPE
- Screening for Heart Attack Prevention and Education
- SIGN
- Scottish Intercollegiate Guidelines Network
- UK
- United Kingdom
- WHO
- World Health Organization
- WPR-A
- Western Pacific Region A
